Akeso falls 6% as FDA declines ivonescimab U.S. applicationMarket Movers·Nov 20, 2026 at 01:51 AM09926-7.05%
CICC: CSPC PHARMA 3Q Results In Line, Core Business Remains SolidAASTOCKS News·Nov 20, 2026 at 05:26 AM01093-4.58%
HSBC Research Raises INNOVENT BIO TP to HKD133 as Johnson & Johnson Acquires Overseas Pipeline Partner OllinAASTOCKS News·Nov 20, 2026 at 09:25 AMJNJ-2.04%01801-6.26%
CSPC PHARMA Receives USD15 million Development Milestone Payment for CRB-701AASTOCKS News·Nov 19, 2026 at 09:31 AM01093-4.58%
CSPC Pharmaceutical Group: Revenue, licensing income and pipeline milestones advanced alongside a 73.6% 1-9M gross marginQuartr·Nov 18, 2026 at 06:51 AM01093-4.58%
CMBI Cuts AKESO TP to HKD99.34; HARMONi-3 Remains Key CatalystAASTOCKS News·Nov 18, 2026 at 05:48 AM09926-7.05%
G Sachs Raises CSPC PHARMA TP to HKD12.83; 3Q Results BeatAASTOCKS News·Nov 19, 2026 at 07:18 AM01093-4.58%
CSPC Reports Nine-Month Revenue and Profit Growth in 2026Tip Ranks·Nov 18, 2026 at 04:38 AM01093-4.58%
M Stanley: CSPC PHARMA 3Q Finished Drug Sales Slightly Beat Expectations, Multiple Pipeline Catalysts ExpectedAASTOCKS News·Nov 19, 2026 at 08:26 AM01093-4.58%
Citi Raises CSPC PHARMA TP to HKD15 as 3Q Results BeatAASTOCKS News·Nov 19, 2026 at 03:43 AM01093-4.58%
CSPC Pharmaceutical Group: AstraZeneca licence income and finished-drug growth lifted 9M revenue 27% and profit 101.5%Quartr·Nov 18, 2026 at 04:14 AM01093-4.58%
China Accepts Akeso’s Ivonescimab Application for Biliary Tract CancerPUBT·Nov 17, 2026 at 03:31 AM09926-7.05%
CLSA Remains Positive on China's Biopharmaceutical Sector, Prefers INNOVENT BIO and SKB BIOAASTOCKS News·Nov 18, 2026 at 07:58 AM01801-6.26%